Avi Biopharma Inc - Current report filing (8-K)
March 31 2008 - 6:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
Earliest Event Reported):
March 28,
2008
AVI
BioPharma, Inc.
(Exact name of Company as
specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
One S.W.
Columbia, Suite 1105
Portland,
OR 97258
(Address of principal
executive offices)
(503)
227-0554
Registrants telephone
number, including area code
Not
Applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
o
|
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other
Events.
In connection with the prospectus supplement dated March 28,
2008, filed with the Securities and Exchange Commission pursuant to Rule 424(b) of
the Securities Act, AVI BioPharma, Inc. (the Company) is filing a copy
of the opinion of Davis Wright Tremaine LLP relating to the legality of the
issuance and sale of the shares in the offering. A copy of the opinion is
attached hereto as Exhibit 5.1.
Item 9.01 Financial
Statements and Exhibits.
(d)
Exhibits
The following exhibits are furnished herewith:
5.1 Opinion
of Davis Wright Tremaine LLP.
23.1 Consent
of Davis Wright Tremaine LLP (contained in Exhibit 5.1)
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Portland, State of Oregon, on March 28, 2008.
|
AVI BioPharma, Inc.
|
|
|
By:
|
/s/ Alan P.
Timmins
|
|
|
|
Alan P. Timmins
|
|
|
President and Chief Operating
Officer
|
|
|
(Principal Operating Officer)
|
|
|
|
|
3
Exhibit Index
Exhibit
|
|
Description
|
|
5.1
|
|
Opinion of Davis Wright Tremaine LLP.
|
|
|
|
23.1
|
|
Consent of Davis Wright Tremaine LLP (contained in
Exhibit 5.1)
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024